Australian biotech progresses with orphan multiple myeloma candidate
This article was originally published in Scrip
Executive Summary
Australian therapeutic antibody company Immune System Therapeutics (IST) is expanding the Phase II trial of its lead anticancer candidate MDX-1097 in Australia following encouraging responses from the first dosed patients and a positive review of safety and efficacy data by an independent data monitoring committee. The product has also received orphan drug designation from the US FDA, the company noted.